Perspective Therapeutics closes $89.8M combined public offering and Lantheus private placement

Perspective Therapeutics, Inc.

Gross proceeds: $69.0M from public offering + $20.8M from private placement = $89.8M total.
Public offering: 156.4M shares at $0.37/sh and pre-funded warrants for 30.1M shares at $0.369/sh.
Private placement to Lantheus: 56.3M shares at $0.37/sh for $20.8M gross.
Proceeds to fund R&D, clinical trials, manufacturing, and potential acquisitions.
Underwriters' option for 24.3M additional shares was exercised in full.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Perspective Therapeutics, Inc. entered into Underwriting Agreement with Oppenheimer & Co. Inc., as representative of the underwriters valued at approximately $69.0 million (effective 2024-01-17).

Action: entry
Agreement: underwriting
Counterparty: Oppenheimer & Co. Inc., as representative of the underwriters
Value: approximately $69.0 million
Effective: 2024-01-17

Exact text from the filing

On January 17, 2024, Perspective Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Oppenheimer & Co. Inc., as representative of the underwriters named therein (the “Underwriters”), in connection with its previously announced underwritten public offering (the “Public Offering”) of 132,075,218 shares

View on SEC.gov

230 material agreements filed in the last 30 days. Browse all material agreements →

Perspective Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-24-001852

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.